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Abstract
Background: Environmentally driven immune activation was suggested to contribute to high rates
of HIV-1 infection in Africa. We report here a study of immune activation markers and
susceptibility to HIV-1 infection in vitro of forty-five highly exposed uninfected partners (EUs) of
HIV-1 infected individuals in Central African Republic, in comparison with forty-four low-risk blood
donors (UCs).
Results: Analysis of T lymphocyte subsets and activation markers in whole blood showed that the
absolute values and the percentage of HLA-DR+CD4 T cells and of CCR5+CD4 T cells were lower
in the EUs than in the UCs (p = 0.0001). Mutations in the CCR5 coding region were not found in
either group. Susceptibility to in vitro infection of unstimulated peripheral blood mononuclear cells,
prior of PHA activation, was decreased in EUs compared to UCs, either using a CXCR4-tropic or
a CCR5-tropic HIV-1 strain (p = 0.02 and p = 0.05, respectively). Levels of MIP-1β, but not of MIP-
1α or RANTES, in the supernatants of PHA-activated PBMC, were higher in the EUs than in the
UCs (p = 0.007).
Conclusion: We found low levels of CD4 T cell activation and reduced PBMC susceptibility to
HIV-1 infection in Central African EUs, indicating that both may contribute to the resistance to
HIV-1 infection.
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Background
Central African Republic (CAR) has a high prevalence rate
of HIV-1 infection estimated at 18% among pregnant
women [1]. The primary route of transmission is hetero-
sexual. High rates of infection in HIV-1-infected individu-
als in Africa have been suggested to be related to immune
hyperactivation driven by environmental factors, includ-
ing high exposure to infectious agents and poor hygienic
conditions [2]. Indeed, higher levels of CD4 and CD8 T
cell activation have been reported in HIV-1 infected Afri-
cans in comparison with European populations [3]. In
particular, HLA-DR expression on CD4 T cells was corre-
lated with CD4 T cell count, viral load and coinfections
[4]. Successful antiretroviral therapy was reported to
decrease the levels of T cell activation markers, with a
stronger effect on CD8 than on CD4 T cell activation [4,5].
A pattern of immune activation, including an increase of
activated T cell subsets and of the HIV-1 CCR5 co-receptor
expression, has been reported not only in HIV-infected
but also in HIV-uninfected African populations [6-9].
Interestingly, peripheral blood mononuclear cells
(PBMC) from individuals with a chronic immune activa-
tion exhibited higher susceptibility to HIV-1 infection in
vitro [10].
In spite of the spreading of HIV-epidemic in CAR, a con-
sistent proportion of Central Africans who have been per-
sistently exposed for several years to infection through
unprotected sexual relationships with HIV-1 infected part-
ners remained seronegative (Bégaud E. et al., unpublished
data). Most studies on correlates of protection against
HIV-1 infection in seronegative exposed individuals in
other African countries were conducted on cohorts of
commercial sex workers (CSW) whereas only a few studies
concerned seronegative partners in serodiscordants cou-
ples [11-18]. In these studies, HIV-1-specific helper and
cytotoxic T cell responses have been detected in a signifi-
cant proportion of exposed seronegative individuals [19-
23]. HIV-1-specific mucosal IgA were also detected in per-
sistently negative Kenyan CSW and were shown to be
capable of in vitro neutralization of HIV-1 [24,25]. The
question of whether these specific immune responses
exert a protective role or they reflect exposure to HIV-1 is,
however, still debated [26-28]. Other immunological or
genetic factors potentially related to the resistance have
also been addressed in exposed seronegative African indi-
viduals but no clear protective mechanisms emerged from
these studies [12,13,29-31]. Genetic polymorphism in the
CCR5 gene, such as the CCR5-Δ32 mutation, which was
associated to the resistance to HIV-1 infection in Cauca-
sian populations, has not been found in Africans [32].
We studied a group of exposed seronegative partners of
HIV-1 infected individuals in Bangui with a long history
of leading a common life and practicing unprotected sex-
ual relations. Considering the background of immune
activation reported in African populations, we asked
whether differences in the levels of CD4 T cell activation
and in the capacity to replicate HIV-1 in vitro could be
related to the apparent resistance to infection in this
group. From the studies conducted, we found lower levels
of CD4 T cell activation and reduced in vitro susceptibility
to HIV-1 infection in exposed seronegative individuals
than in low-risk Central African blood donors.
Results
Characteristics of study population
Forty-five EU partners of HIV-1 infected individuals were
included in the study. Median common life with unpro-
tected sex relations was estimated to be 8 years (Table 1).
At the time of enrollment, most HIV-1 infected partners
were consulting for clinical symptoms related to HIV-1
infection. Median CD4 T cell count of HIV-1 infected part-
ners was 73 cells/μl (IQR: 26-227) and median plasma
viral load was 7.2 × 104 copies/ml (IQR: 1.3 × 104 – 14.8
× 104). Altogether, the clinical and virological characteris-
tics of HIV-1 infected individuals suggested a long-term
infection and a history of high risk exposure for their part-
ners. There were no significant differences in potential risk
factors for infection between the serodiscordant couples
and 243 couples consulting at the Communitarian Hospi-
tal of Bangui in which both partners were seropositive
(not shown). Among UCs, 73% were men and 27%
women, with a median age of 24 years (18–40).
Table 1: Characteristics of the EUs n = 45
Sex:
Male 45 %
Female 55 %
Age (years): 35 (18–52)*
Common life (years): 8 (2–27)*
Sexual intercourses/week : 2 (1–5)*
Never using condom : 84.2 %
STI antecedents: 5.6 %
Circumcised men: 81.6 %
*Median (min-max)Retrovirology 2006, 3:35 http://www.retrovirology.com/content/3/1/35
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The analysis of the CCR5 coding region polymorphism
did not reveal the presence of variants of the CCR5 co-
receptor, including the CCR5Δ32 mutation, among EUs
or UCs.
Decreased expression of HLA-DR and CCR5 on CD4 T 
cells from EUs
In order to evaluate a potential role of immune activation
and co-receptor expression in the susceptibility to HIV-1
infection, we examined lymphocyte subsets, expression of
activation markers (HLA-DR and CD38) and HIV-1 co-
receptors (CXCR4 and CCR5) on T cells in fresh whole
blood from 25 EUs and 24 UCs. We did not find differ-
ences in CD4 or CD8 T cells, B and NK cells (absolute val-
ues and percentages) between the two groups (Table 2).
However, the absolute value and the percentage of HLA-
DR+CD4 T cells were significantly lower in the EUs than
in the UCs (p = 0.0001) (Table 2). We also found lower
absolute value and percentage of CCR5-expressing CD4 T
cells in the EUs than in the UCs (p = 0.0001) (Table 2).
CCR5 and HLA-DR expression on CD4 T cells were highly
correlated (r = 0.80, p < 0.0001). Conversely, the absolute
value and the percentage of CXCR4-expressing CD4 T cells
did not differ between EUs and UCs. Furthermore, no dif-
ferences were found in the expression of activation mark-
ers or of CXCR4 and CCR5 on CD8 T cells (Table 2).
Reduced PBMC susceptibility to in vitro HIV-1 infection in 
EUs
We evaluated PBMC susceptibility to in vitro infection
using two HIV-1 strains with different tropisms, HIV-1
NL-4.3 (X4) and HIV-1 BaL (R5). In order to evaluate the
impact of the baseline activation of PBMC on their suscep-
tibility to infection, we inoculated PBMC with the virus
without any previous exogenous stimulation (infection
before activation, BA) and then activated PBMC with PHA
to allow efficient viral replication. In parallel, we also
infected 3-days PHA activated PBMC (infection after acti-
vation, AA). The levels of p24 produced in infected cul-
tures were expressed as percentages of those produced in
parallel infections of standard PBMC (Fig. 1). In BA infec-
tivity assays, we found lower p24 levels in PBMC from
EUs than in PBMC from UCs after infection with either
NL-4.3 (p = 0.02) or HIV-1 BaL (p = 0.05) (Fig 1A,B). In
AA infectivity assays, no significant differences between
EU and UC were found for both NL-4.3 and BaL infec-
tions, although p24 production in BaL infected PBMC
were lower in the EUs than in the UCs (medians: 87 and
113 in EUs and UCs respectively, p = 0.12). We also per-
formed infectivity assays using one CAR primary HIV-1
isolate on PBMC from 30 EUs and 35 UCs. BA infectivity
assays with this CAR primary HIV-1 isolate indicate a
lower virus production, evaluated by p24 levels in PBMC
supernatants, in EUs than in UCs, as observed with BaL
and NL-4.3 viruses. However, the difference did not reach
statistical significance, because of the lower number of
subjects analyzed (percentages of infection were 26 [0–
124] and 49 [4.3–327] in EUs and UCs respectively (p =
0.14). In AA infectivity assays with the primary isolate,
percentages of infection were 76 [7.9–392] and 117.3
[9.1–449.5] in EUs and UCs respectively.
β-chemokine secretion by PBMC
We found a higher level of MIP-1β/CCL4 production in
PHA-activated PBMC supernatants from the EUs than
from the UCs (medians: 43.7 and 28.9 ng/ml in EUs and
Table 2: Lymphocyte subsets and activation markers in the EUs and UCs
Lymphocyte subsets EUs (n = 25) UCs (n = 24) p-value°
Lymphocytes * 2500 (2052–3031) 2184 (1800–2632) 0.26
CD3 (%)* 72 (69–77) 73 (70–80) 0.27
CD4 (%)* 42 (32–46) 42 (34–45) 0.98
CD8 (%)* 28 (23–33) 28 (25–33) 0.63
NK (%)* 17 (13–22) 14 (11–18) 0.19
T cell markers
(T cell subset)#
HLA-DR (CD4+)* 138.6 (61–208) 288.7 (217–403) 0.0001
CD38 (CD4+)* 527.6 (267 – 862) 269.5 (238–410) 0.13
HLA-DR (CD8+)* 200 (124–285) 280.1 (165–360) 0.13
CD38 (CD8+)* 370 (194–527) 312.3 (244–441) 0.87
CXCR4 (CD4+)* 1041 (475–1233) 579.2 (221–895) 0.11
CCR5 (CD4+)* 44.1 (26.9–88.7) 146.5 (92.4–312) 0.0001
CXCR4 (CD8+)* 470.2 (298–747) 323.2 (155–500) 0.17
CCR5(CD8+)* 250.5 (164–293) 169.3 (106–245) 0.20
* Median (Q1–Q3)
° Mann-Whitney U test. After Bonferroni correction the level of significance was set at 0.004
# Absolute valuesRetrovirology 2006, 3:35 http://www.retrovirology.com/content/3/1/35
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Susceptibility of peripheral blood mononuclear cells to in vitro HIV-1 infection Figure 1
Susceptibility of peripheral blood mononuclear cells to in vitro HIV-1 infection. PBMCs (105 cells/well in 96-well 
microplates) from 45 EUs and 44 UCs were infected with HIV-1 NL-4.3 (A) or with HIV-1 BaL (B) in quadruplicate. Infections 
were performed either 24 h before PHA activation of PBMC (BA), or after 3-days PHA activation (AA). Standard PBMC were 
infected in parallel in each assay. HIV-1 replication was monitored by p24 antigen measure in culture supernatants. The p24 val-
ues of each individual PBMC infection were compared to the mean p24 value of standard PBMC. Results are expressed as the 
percent of the standard PBMC supernatant p24 at the peak of infection. Box-plots represent the 25th and the 75th percentiles 
and bars indicate the lowest and the highest values. The horizontal line in the boxes indicates the median. Comparisons 
between the groups were made using the non parametric Mann-Whitney U test.Retrovirology 2006, 3:35 http://www.retrovirology.com/content/3/1/35
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UCs respectively, p = 0.007), whereas there were no signif-
icant differences in MIP-1α/CCL3 (medians: 20.9 and
19.2 in EUs and UCs) or RANTES/CCL5 (medians: 30.8
and 22.4 in EUs and UCs) between the two groups.
Discussion
Immune activation has been suggested to be critical in
HIV-1 transmission and spreading in sub-Saharan Africa.
We studied a group of Central African individuals who
remained apparently uninfected despite repeated unpro-
tected sex intercourses with their HIV-1-infected partners
(EUs). We found a lower number and proportion of acti-
vation marker-expressing CD4 T lymphocytes in the EUs
than in the low-risk controls. HLA-DR+CD4 T cell levels in
UCs were indeed comparable to those reported for other
African populations [13]. These data suggest lower availa-
bility of activated CD4 T cells for efficient HIV-1 replica-
tion in Central African EUs. Accordingly, PBMC from the
EUs were less susceptible to both X4 and R5 HIV-1 strains
in comparison with PBMC from the UCs, when infected
before PHA-stimulation. In this condition, differences in
target cell basal activation between the EUs and the UCs
may eventually result in different capacity to support viral
infection and replication. A higher number of activated
CD4 T cells in UCs may allow a more rapid onset of HIV-
1 replication, which would then promote a more efficient
spread of infection upon PHA-activation. The loss of dif-
ference in HIV-1 replication levels between EUs and UCs
when PBMC were activated before infection may be due to
the strong polyclonal stimulation by PHA that may mask
the initial differences in the susceptibility to HIV-1 infec-
tion. Still, the levels of HIV-1 Bal production were lower
in the EUs PBMC, possibly due to higher production of
MIP-1β. Contrasting results have been reported in this
regard, depicting either lower or comparable susceptibil-
ity to HIV-1 infection of PHA-stimulated PBMC in differ-
ent EU groups in comparison to control groups [12,30,33-
36]. However, whether discrepancies are linked to differ-
ences in experimental conditions or to differences
between populations of study remains unclear
Consistent with the low CD4 T cell activation, EUs also
showed a significantly lower expression of CCR5 on CD4
T lymphocytes. CCR5 surface expression has been shown
to influence in vitro infectability with R5 HIV-1 [37-41]
and R5 variants are largely prevalent in infected individu-
als in Bangui [42]. Therefore, low levels of CCR5-express-
ing CD4 T cells may actually contribute to protect Central
African EUs from HIV-1 transmission.
A recent study has also associated lower levels of CD4 T
cell activation with resistance to HIV-1 in a group of
homosexual EUs from the Amsterdam Cohort Studies
[43]. In this study, lower percentages of CXCR4 – but not
of CCR5-expressing CD4 T cells were found in EUs. How-
ever, lymphocyte phenotypes were determined on cryop-
reserved PBMCs and not in fresh blood, as we did, and the
surface expression of CXCR4 and CCR5 may vary accord-
ing to the nature and the conservation of samples [44] and
Scott-Algara D. et al. unpublished data). A CXCR4
decreased expression in CD4 T cells from commercial sex
workers in Côte d'Ivoire was associated with prolonged
duration of commercial sex work and not with T cell acti-
vation [13]. It is possible that parameters associated with
different sexual behaviours and/or environments are
involved in the regulation of chemokine receptors expres-
sion.
Conclusion
In summary, we found low CD4 T cell activation and
CCR5 expression as well as a reduced susceptibility to
HIV-1 infection in Central African EU partners of HIV-1
infected individuals. This study did not allow further
examination of immune activation or HIV-specific
responses in other lymphoid compartments, including
genital mucosa that is particularly relevant in sexual trans-
mission of HIV-1. Previous studies of parameters of pro-
tection in EU CSW in Kenya revealed higher frequencies of
CTL, CD4 T cells, IgA or elevated levels of β-chemokines
in cervico-vaginal samples than in blood [16,21,24].
However, low levels of systemic CD4 T cell activation as
well as a reduced susceptibility to HIV-1 infection docu-
mented here may reflect a general lower permissiveness to
infection in EUs and may contribute to the protection
against HIV-1 transmission, possibly together with other
anti-viral responses not addressed here. Indeed, EUs are
heterogeneous populations and different mechanisms,
either innate or acquired, likely account for protection in
different individuals [45-47].
Materials and methods
Study population
Forty-five HIV-1-positive individuals and their HIV-1-neg-
ative heterosexual partners having a history of regular
unprotected sexual relations for more than two years were
enrolled at the Communitarian Hospital in Bangui. Sero-
positive patients were admitted in the hospital for medical
care. Plasma HIV-1 RNA levels were quantified using the
HIV-1 RNA 3.0 assay (Chiron, France). Partners of HIV-1
infected patients were tested negative for HIV-1 infection
by Genelavia Mixt (Sanofi Diagnostics Pasteur) and
Vironostica HIV Uni-form II (Organon Teknika) and by
PCR on PBMC DNA for gag, pol, and env genes and will
therefore be referred to as exposed uninfected individuals
(EUs). All PCR primers used allow amplification of most
HIV-1 isolates of the M group, including A subtype env
that is predominant in CAR [48]. Enrolled participants
gave their informed consent, completed a questionnaire
regarding the frequency of sexual relations and other risk
practices and received counseling and information aboutRetrovirology 2006, 3:35 http://www.retrovirology.com/content/3/1/35
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HIV-1 and safe sex. Forty-four Central African HIV-1
seronegative individuals with no risk factors for HIV-1
infection, such as sex with multiple partners or intrave-
nous drug use, were recruited in Bangui as unexposed con-
trols (UCs). This study was approved for ethical clearance
by CAR Health Ministry and Health Authorities.
The political situation in CAR, including a coup in March
2003, caused movements of population including indi-
viduals enrolled in this study. Consequently, most of the
analyses described below were performed on blood sam-
ples collected only at baseline visit.
CCR5 polymorphism analysis
CCR5 coding region polymorphism in EUs was analysed
by denaturing high performance liquid chromatography
and sequencing, as previously described [49]
Flow cytometry
Immunophenotyping analyses were performed on fresh
whole blood samples from EUs or UCs at the Institut Pas-
teur of Bangui. CD4, CD8, NK and B cell populations
were studied by a three-colour flow cytometry with stand-
ard lysis procedures. Labelled cells were analysed on a
FACSCalibur flow cytometre (Becton Dickinson, Paris,
France) (10000 events in lymphocyte gate). Monoclonal
antibodies were acquired from Becton Dickinson.
Infectivity assays
Peripheral blood mononuclear cells (PBMCs) were pre-
pared from blood samples collected on EDTA by centrifu-
gation on Ficoll-Paque Plus (Amersham Bioscience,
Uppsala, Sweden) and cryopreserved in fetal calf serum
(FCS, Life Technologies) – 10 % dimethyl sulphoxide
(Sigma, Irvine, UK). Susceptibility of PBMC to HIV-1
infection was determined by using the CCR4-tropic (X4)
NL-4.3 HIV-1 or the CCR5-tropic (R5) BaL HIV-1 strains.
In some experiments we also used a primary R5/(X4) iso-
late, HIV-1 73Mcd, from one CAR HIV-1-infected partner
of an EU. To reduce inter-experimental variability bias, we
included a same reference stock of PBMC from a HIV-
blood donor used as standard in each assay and desig-
nated thereafter "standard PBMC". Viral inoculums able
to consistently infect standard PBMCs were determined in
preliminary assays. For each individual, PBMCs (105 cells/
well in 96-well microplates) were infected in quadrupli-
cate either 24 h before being activated with PHA (1 μg/ml)
for 3 days (infection before activation: BA), or after 3-days
activation with PHA (infection after activation: AA).
PBMCs were then cultured in RPMI 1640 medium con-
β-chemokine levels in PBMC supernatants Figure 2
β-chemokine levels in PBMC supernatants. PBMC culture supernatants were collected after a 3-day-PHA-activation and 
levels of MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 were measured by ELISA. Box-plots show the median values and 
percentiles of the levels of each β-chemokine expressed in ng/ml. Comparisons between the groups were made using the 
Mann-Whitney U test.Retrovirology 2006, 3:35 http://www.retrovirology.com/content/3/1/35
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taining 10% FCS, 1% penicillin-streptomycin-neomycin,
1% glutamine and 100 U.I. of IL2 (Proleukin; Chiron,
France) and HIV-1 replication was monitored by p24 anti-
gen quantification in culture supernatants (HIV-1 p24
Antigen Assay, Coulter, France). The p24 value of stand-
ard PBMCs at their peak of infection (day 10–13) was con-
sidered to be 100 % for each infectivity assay. The p24
values of each individual PBMC infection were compared
and normalised to the mean p24 value of the standard
PBMC. Infectivity assays were performed in the L3 labora-
tory of the Institut Pasteur of Bangui.
β-chemokine production
β-chemokine (MIP-1α/CCL3, MIP-1β/CCL4, RANTES/
CCL5) levels in PHA-activated PBMC supernatants were
measured using commercial ELISA kits according to the
manufacturer's instructions (Quantikine R&D Systems,
Oxon, UK).
Statistical analysis
Statistical analysis was performed by using the STATA 8.0
statistical package (Stata Corporation, College Station,
Texas, USA). Continuous variables were compared
between the groups using the non-parametric Mann-
Whitney U test. A Bonferroni correction was applied to
the level of significance of statistical tests for comparing
lymphocyte phenotypes between EU and controls due to
the large number of tests performed in this analysis. Based
on 13 comparisons of phenotypes, the level of signifi-
cance was set at 0.05/13 = 0.004. Spearman rank correla-
tion coefficients were computed to assess the strength of
the association between two continuous variables.
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